pharmaphorum

Generate's IPO gets over the line, raising $400m

Generate Biomedicines has completed its IPO, raising an impressive $400 million that makes it the largest listing for a biotech on the Nasdaq so far this year. Incubated by investment group Flagship ...

Minecraft 26.2 Snapshot 6 Adds New Sulfur Cube Type and Reverts Sulfur Biome Change

Minecraft 26.2 Snapshot 6 brings new Sulfur Cube archetypes, updates the Sulfur Caves, and adds support for new languages.
TheServerSide

Connect Java apps to ChatGPT using OpenAI and Spring Boot

If you've ever wanted to integrate OpenAI's ChatGPT features into your Java programs, you'll be happy to learn that Spring AI has made the process easier than ever. And it's not just easier to connect ...
Forbes

Generate Biomedicines IPO Turns Heads

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...
Reuters

Generate Biomedicines shares fall in weak Nasdaq debut for drug developer

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...
MedCity News

Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...
Bloomberg L.P.

Flagship-Backed Generate Biomedicines Raises $400 Million in IPO

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...
Yahoo Finance

Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering

SOMERVILLE, Mass., Feb. 26, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (Nasdaq: GENB) ("Generate"), a clinical-stage generative biology company pioneering the AI revolution in biotechnology and ...
The Boston Globe

Flagship-backed Generate Biomedicines seeks $425 million in IPO

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...
Seeking Alpha

Generate Biomedicines Begins IPO Push With Major Collaboration Deals

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...
The Business Journals

Generate:Biomedicines eyes public markets as AI drug advances to late-stage trials

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Generate:Biomedicines raised ...